# Vagus Nerve Stimulation **Entity class:** Therapy and device class **Domain:** Bioelectronic Medicine / Peripheral Neuromodulation **Doc Type:** Technology Node **Maturity:** Commercial (implanted); investigational for wearable depression use **Collection:** [[collections/Neurotech|Neurotech]] **Primary Sources:** [[research/Research Inferences|Research Inferences]] (INF-0047, INF-0305, INF-0306) ## Definition **Vagus nerve stimulation (VNS) delivers electrical pulses to the vagus nerve, the main parasympathetic pathway between the brainstem and the heart, lungs and gut, to modulate brain and body states.** Implanted cervical VNS has been FDA-approved for epilepsy since 1997 and for treatment-resistant depression since 2005. Non-invasive variants stimulate the auricular branch at the ear or the cervical branch through the skin of the neck; wearable auricular stimulation for depression remains investigational in the United States as of this writing. ## Clinical record - **Epilepsy (1997)** and **treatment-resistant depression (2005):** implanted cervical VNS, the device line now held by LivaNova. - **Stroke rehabilitation (2021):** the Vivistim system pairs VNS with motor therapy for upper-limb recovery after stroke. - **Headache:** non-invasive cervical stimulation (gammaCore) holds FDA clearance for cluster headache and migraine. - **Inflammation:** stimulation modulates systemic inflammatory signaling through the inflammatory reflex, the founding demonstration of bioelectronic medicine. - **Wearable depression therapy:** *Med-X* reviewed wearable auricular and cervical VNS for treatment-resistant depression, mechanisms from monoamines to brain networks, device design and AI-driven closed-loop personalization (25 August 2026). No 2026 FDA clearance for a wearable depression device was located. ## Forward Capability VNS is the access point where peripheral neuromodulation, closed-loop control and consumer hardware meet. The nerve is reachable without a craniotomy, its traffic regulates organs as well as mood, and a wearable stimulator shifts the adaptive logic from the device to the model that tunes it. A wearable clearance for depression would give the networked-body cluster its first non-invasive prescription node, and it would place one of the four top BCI indications named by the [[wiki/Med-X BCI-2035 Perspective|Med-X BCI-2035 Perspective]] within reach of an ear-worn device. ## Open Questions - The first FDA clearance or De Novo grant for a wearable VNS depression device. - Comparative effect sizes for auricular versus cervical approaches in controlled trials. - Whether AI-personalized parameter tuning is regulated as part of the device or as separate software. ## Research Inferences These entries translate the forward-looking register in [[research/Research Inferences|Research Inferences]] into ordinary wiki prose. The tier labels apply to the inference, not automatically to every factual anchor inside it. Proposed IDs above INF-0500 and tier recommendations come from the 2026-10-23 cycle: [[research/Research Inferences Integration Report - 2026-10-23|Research Inferences Integration Report — 2026-10-23]] · [[research/Research Inferences Integration Audit - 2026-10-23|Research Inferences Integration Audit — 2026-10-23]]. - **INF-0047 — Strongly indicated.** The peripheral nervous system is accessible without craniotomy and carries organ-regulatory traffic, which makes it the first place where continuous closed-loop control of the body's internal state becomes routine. Central interfaces will inherit a control theory developed peripherally. - **INF-0305 — Established.** Stimulating the vagus modulates systemic inflammatory signaling through a defined neural reflex, which means an electrical device can set an immunological parameter. Electricity substituting for a drug is the founding demonstration of bioelectronic medicine, and its indications expand annually. - **INF-0306 — Strongly indicated.** A stimulation parameter can be changed instantly and reversibly, while a pharmaceutical dose cannot be recalled once administered. Reversibility gives electrical therapeutics a control-theoretic advantage that will move indications from drugs to devices wherever a nerve carries the signal. - **INF-0371 — Plausible.** Non-invasive stimulation devices operated under remote supervision extend neuromodulation to people who will never see a specialist. Scale of reach, not depth of effect, is what makes remote neuromodulation strategically significant. - **INF-0502 (proposed) — Plausible.** Wearable closed-loop VNS with AI-driven personalization moves adaptation from hardware to model; a wearable clearance would give Cluster M its first non-invasive prescription node. ## Relationships - **indication:** [[wiki/Treatment-Resistant Depression|Treatment-Resistant Depression]]. - **reviewed_in:** [[wiki/Med-X|Med-X]] (wearable VNS review, 25 August 2026). - **priority_match:** [[wiki/Med-X BCI-2035 Perspective|Med-X BCI-2035 Perspective]] (depression and anxiety among the four top targets). - **implanted_peer:** [[wiki/Motif Neurotech|Motif Neurotech]] (cranial depression stimulator, April 2026 IDE). - **instance_of:** [[wiki/Closed-Loop Neuromodulation|Closed-Loop Neuromodulation]]. - **cluster_home:** [[wiki/In-Body Regulation and Autonomous Physiology|In-Body Regulation and Autonomous Physiology]] (INF-0305 placement) · [[wiki/Networked Body|Networked Body]] · [[wiki/Distributed Biological Interfaces|Distributed Biological Interfaces]]. - **ecosystem:** [[wiki/Neurotechnology Ecosystem|Neurotechnology Ecosystem]] · [[collections/Neurotech|Neurotech]]. ## Sources - [Wearable vagus nerve stimulation for depression: mechanisms, devices, and the road toward personalized neuromodulation — Med-X, 25 August 2026](https://link.springer.com/article/10.1007/s44258-026-00092-8) - [The future is noninvasive: a brief review of the evolution and clinical utility of vagus nerve stimulation — Frontiers in Neurology (via PMC), 2022](https://pmc.ncbi.nlm.nih.gov/articles/PMC9093220/) - [Treating depression with transcutaneous auricular vagus nerve stimulation — Frontiers in Psychiatry (via PMC), 2018](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5807379/) As of 23 October 2026.